Molecular Cancer Research Funding AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rossi, S.
Right arrow Articles by Loda, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rossi, S.
Right arrow Articles by Loda, M.
Molecular Cancer Research 1:707-715 (2003)
© 2003 American Association for Cancer Research


Cancer Genes and Genomics

Fatty Acid Synthase Expression Defines Distinct Molecular Signatures in Prostate Cancer1

Sabrina Rossi1, Edgard Graner1, Phillip Febbo1, Lisa Weinstein1,2, Nandita Bhattacharya1, Tamas Onody1, Glenn Bubley3, Stephen Balk3 and Massimo Loda1,2,4

Department of Medical Oncology, Dana-Farber Cancer Institute; Department of Pathology, Brigham and Women's Hospital; Department of Medicine, Beth Israel Deaconess Medical Center; Harvard Medical School, Boston, MA; and Regina Elena Cancer Institute, Rome, Italy

Requests for reprints: Massimo Loda, Department of Medical Oncology, Dana-Farber Cancer Institute, D-740B, 44 Binney Street, Boston, MA 02115. Phone: (617) 632-4005. E-mail: massimo_loda{at}dfci.harvard.edu

The androgen-regulated enzyme fatty acid synthase (FAS), required for de novo lipogenesis, is overexpressed in several cancers including prostate carcinoma and has been associated with aggressive disease. FAS expression was assessed in 81 prostate carcinomas, both by immunohistochemistry in tissue microarrays and by Affymetrix Hu95Av2 oligonucleotide arrays. Both FAS mRNA and protein were significantly overexpressed in prostate carcinomas compared with the corresponding normal tissue. FAS mRNA and protein expression increased substantially from normal to prostatic intraepithelial neoplasia, to low grade, to high grade, and to androgen-independent bone metastases. A significant correlation between FAS mRNA and protein expression was found in two thirds of the cases. In 17% of the cases, FAS protein levels were high despite low mRNA levels, and these tumors exhibited a distinct molecular signature when compared with tumors that did not express FAS protein. Whereas the latter group of tumors expressed some proapoptotic genes, tumors with high FAS levels overexpressed, among other genes, its transcriptional regulator, steroid regulator binding protein, and apolipoprotein E. These data demonstrate (1) the consistent overexpression of FAS in prostate carcinoma compared with the adjacent normal tissue, (2) a strong association between FAS and prostate tumor initiation and progression, (3) the highest FAS expression occurring in androgen-independent bone metastases, (4) the transcriptional and posttranscriptional regulation of FAS in the majority and in a subset of prostate cancers, respectively, and (5) most importantly, the identification by FAS expression of prostate tumors with unique molecular signatures and potentially diverse biologic behavior.

Key Words: fatty acid synthase • prostate cancer • oligonucleotide array • tissue microarray • PIN




This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
C. Wang, M. J. Powell, V. M. Popov, and R. G. Pestell
Acetylation in Nuclear Receptor Signaling and the Role of Sirtuins
Mol. Endocrinol., March 1, 2008; 22(3): 539 - 545.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Ma, R. Yan, X. Zu, J.-M. Cheng, K. Rao, D.-F. Liao, and D. Cao
Aldo-keto Reductase Family 1 B10 Affects Fatty Acid Synthesis by Regulating the Stability of Acetyl-CoA Carboxylase-{alpha} in Breast Cancer Cells
J. Biol. Chem., February 8, 2008; 283(6): 3418 - 3423.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
A. L. Vavere, S. J. Kridel, F. B. Wheeler, and J. S. Lewis
1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer
J. Nucl. Med., February 1, 2008; 49(2): 327 - 334.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. D. Richardson and J. W. Smith
Novel antagonists of the thioesterase domain of human fatty acid synthase
Mol. Cancer Ther., July 1, 2007; 6(7): 2120 - 2126.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
O. M. Sinilnikova, J. D. McKay, S. V. Tavtigian, F. Canzian, D. DeSilva, C. Biessy, S. Monnier, L. Dossus, C. Boillot, L. Gioia, et al.
Haplotype-Based Analysis of Common Variation in the Acetyl-CoA Carboxylase {alpha} Gene and Breast Cancer Risk: A Case-Control Study Nested within the European Prospective Investigation into Cancer and Nutrition
Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 409 - 415.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. L. Little, F. B. Wheeler, D. R. Fels, C. Koumenis, and S. J. Kridel
Inhibition of Fatty Acid Synthase Induces Endoplasmic Reticulum Stress in Tumor Cells
Cancer Res., February 1, 2007; 67(3): 1262 - 1269.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. Fu, M. Liu, A. A. Sauve, X. Jiao, X. Zhang, X. Wu, M. J. Powell, T. Yang, W. Gu, M. L. Avantaggiati, et al.
Hormonal Control of Androgen Receptor Function through SIRT1
Mol. Cell. Biol., November 1, 2006; 26(21): 8122 - 8135.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
C. D. Browne, E. J. Hindmarsh, and J. W. Smith
Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor
FASEB J, October 1, 2006; 20(12): 2027 - 2035.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
H. V. Heemers, G. Verhoeven, and J. V. Swinnen
Androgen Activation of the Sterol Regulatory Element-Binding Protein Pathway: Current Insights
Mol. Endocrinol., October 1, 2006; 20(10): 2265 - 2277.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Priolo, D. Tang, M. Brahamandan, B. Benassi, E. Sicinska, S. Ogino, A. Farsetti, A. Porrello, S. Finn, J. Zimmermann, et al.
The Isopeptidase USP2a Protects Human Prostate Cancer from Apoptosis.
Cancer Res., September 1, 2006; 66(17): 8625 - 8632.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. Lupu and J. A. Menendez
Targeting Fatty Acid Synthase in Breast and Endometrial Cancer: An Alternative to Selective Estrogen Receptor Modulators?
Endocrinology, September 1, 2006; 147(9): 4056 - 4066.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Bandyopadhyay, R. Zhan, Y. Wang, S. K. Pai, S. Hirota, S. Hosobe, Y. Takano, K. Saito, E. Furuta, M. Iiizumi, et al.
Mechanism of Apoptosis Induced by the Inhibition of Fatty Acid Synthase in Breast Cancer Cells
Cancer Res., June 1, 2006; 66(11): 5934 - 5940.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
X. Liu, Y. Shi, V. L. Giranda, and Y. Luo
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis.
Mol. Cancer Ther., March 1, 2006; 5(3): 494 - 501.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.